Effect of Bergamot Polyphenolic Fraction on level of HDL-C & LDL-C

Authors

  • Kanika  Sat Kabir college of pharmacy, Village Ladrawan, Tehsil Bahadurgarh, District Jhajjar.
  • Prashant  Delhi, India

Keywords:

metabolic syndrome (MetS), LDL-C, triglycerides, bergamot Polyphenolic fraction, Cardiovascular

Abstract

A well-established modifiable cardiovascular risk component is low density lipoprotein (LDL-C). Although statins can lessen LDL-c through 50–60%, less than 20% of patients with excessive risk of CVD acquire LDL targets. The purpose of this systematic review is to assess the impact of the nutraceutical, bergamot (Citrus bergamia), on lipid parameters in humans. Based on data, 75% of studies confirmed a significant lower in overall cholesterol, triglycerides and LDL-c. The lower in overall cholesterol varied from 12.3% to 31.3%, from 7.6% to 40.8% in LDL-c and from 11.5% to 39.5% in triglycerides. The incidence of metabolic syndrome (MS) represents an independent risk factor for developing cardiovascular disorder states in patients affected by type 2 diabetes mellitus. Moreover, both the size of LDL particles and liver disorder recognized as non- alcoholic steato-hepatitis (NASH) constitute essential biomarkers for the improvement of cardiometabolic risk in patients with MS. Recent evidence indicates that bergamot polyphenolic fraction (BPF) in patients with MS and NASH induces a significant decrease of fasting plasma glucose, serum LDL cholesterol and triglycerides along with an increase of HDL cholesterol. In addition, a significant reduction of both ultrasonographic, TC scans and metabolic biomarkers of NASH in addition to a significant reduction of small dense LDL particles have been determined after BPF treatment suggesting a useful impact of bergamot-extract in patients with MS and NASH. In this regards, emerging evidence indicates a capability protecting function of bergamot extracts, specially bergamot flavonoids, in the control of various features of MetS (metabolic syndrome), because of their pleiotropic anti-oxidative, anti-inflammatory and lipid- reducing results. The purpose of this review is to discuss the beneficial effects of bergamot polyphenols providing a brand-new therapeutic method in the treatment of cholesterol.

References

  1. Haffner, S.M., Lehto, S., Rönnemaa, T., Pyörälä, K. and Laakso, M. (1998) Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Non Diabetic Subjects with and without Prior Myocardial Infarction. New England Journal of Medicine, 339, 229-234. http://dx.doi.org/10.1056/NEJM199807233390404
  2. Thalhammer, C., Balzuweit, B., Busjahn, A., Walter, C., Luft, F.C. and Haller, H. (1999) Endothelial Cell Dysfunction and Arterial Wall Hypertrophy Are Associated with Disturbed Carbohydrate Metabolism in Patients at Risk for Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 19, 1173-1179. http://dx.doi.org/10.1161/01.ATV.19.5.1173
  3. Juutilainen, A., Lehto, S., Rönnemaa, T., Pyörälä, K. and Laakso, M. (2008) Similarity of the Impact of Type 1 and Type 2 Diabetes on Cardiovascular Mortality in Middle-Aged Subjects.DiabetesCare,31,714-719. http://dx.doi.org/10.2337/dc07-2124
  4. Hu, F.B., Stampfer, M.J., Haffner, S.M., Solomon, C.G., Willett, W.C. and Manson, J.E. (2002) Elevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes. DiabetesCare,25,1129-1134. http://dx.doi.org/10.2337/diacare.25.7.1129
  5. Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.R. and Groop, L. (2001) Cardiovascular Morbidity and Mortality Associated with the Metabolic Syndrome. Diabetes Care, 24, 683-689. http://dx.doi.org/10.2337/diacare.24.4.683.
  6. Sampson, U.K., Fazio, S. and Linton, M.F. (2012) Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges. Current Atherosclerosis Reports, 14, 1- 10. http://dx.doi.org/10.1007/s11883-011-0219-7
  7. Berneis, K., Jeanneret, C., Muser, J., Felix, B. and Miserez, A.R. (2005) Low Density Lipoprotein Size and Subclasses Are Markers of Clinically Apparent and Non-Apparent Atherosclerosis in Type 2 Diabetes. Metabolism, 54, 227-234.
  8. Krauss, R.M. (2004) Lipids and Lipoproteins in Patients with Type 2 Diabetes. Diabetes Care, 27, 1496-1504. http://dx.doi.org/10.2337/diacare.27.6.1496
  9. Rizzo, M., Pernice, V., Frasheri, A., Di Lorenzo, G., Rini, G.B., Spinas, G.A. and Berneis, K. (2009) Small, Dense Low-Density Lipoproteins (LDL) Are Predictors of Cardio and Cerebro-Vascular Events in Subjects with the Metabolic Syndrome. Clinical Endocrinology (Oxf), 70, 870-875. http://dx.doi.org/10.1111/j.1365-2265.2008.03407.x
  10. Austin, M.A., Breslow, J.L., Hennekens, C.H., Buring, J.E., Willett, W.C. and Krauss, R.M. (1988) Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction. JAMA, 260, 1917-1921. http://dx.doi.org/10.1001/jama.1988.03410130125037
  11. Feingold, K.R., Grunfeld, C., Pang, M., Doerrler, W. and Krauss, R.M. (1992) LDL Subclass Phenotypes and Triglyceride Metabolism in Non-Insulin Dependent Diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology, 12, 1496- 1502. http://dx.doi.org/10.1161/01.ATV.12.12.1496
  12. Krayenbuehl, P.A., Wiesli, P., Schmid, C., Lehmann, R., Spinas, G.A. and Berneis, K. (2008) Insulin Sensitivity in Type 2 Diabetes Is Closely Associated with LDL Particle Size. Swiss Medical Weekly, 138, 275-280.
  13. Chait, A., Brazg, R.L., Tribble, D.L. and Krauss, R.M. (1993) Susceptibility of Small, Dense, Low-Density Lipoproteins to Oxidative Modification in Subjects with the Atherogenic Lipoprotein Phenotype, Pattern B. American Journal of Medicine, 94, 350-356. http://dx.doi.org/10.1016/0002-9343(93)90144-E
  14. Younis, N., Charlton-Menys, V., Sharma, R., Soran, H. and Durrington, P.N. (2009) Glycation of LDL in Non-Diabetic People: Small Dense LDL Is Preferentially Glycated Both in Vivo and in Vitro. Atherosclerosis, 202, 162-168. http://dx.doi.org/10.1016/j.atherosclerosis.2008.04.036
  15. American Diabetes Association. Position Statement (2012) American Diabetes Association Standards of Medical Care in Diabetes. Diabetes Care, 35, S11-S63.
  16. Eknoyan, G., Hostetter, T., Bakris, G.L., Hebert, L., Levey, A.S., Parving, H.H., Steffes, M.W. and Toto, R. (2003) Proteinuria and Other Markers of Chronic Kidney Disease: A Position Statement of the National Kidney Foundation (NKF) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). American Journal of Kidney Diseases, 42, 617-622.http://dx.doi.org/10.1016/S0272-6386(03)00826-6
  17. Ong, J.P., Pitts, A. and Younossi, Z.M. (2008) Increased Overall Mortality and Liver-Related Mortality in Non-Alcoholic Fatty Liver Disease. Journal of Hepatology, 49, 608-612. http://dx.doi.org/10.1016/j.jhep.2008.06.018
  18. Wang, Y., Li, Y.Y., Nie, Y.Q., Zhou, Y.J., Cao, C.Y. and Xu, L. (2013) Association between Metabolic Syndrome and the Development of Non-Alcoholic Fatty Liver Disease. Experimental and Therapeutic Medicine, 6, 77-84.
  19. Tarantino, G. (2007) Should Non-Alcoholic Fatty Liver Disease Be Regarded as a Hepatic Illness Only? World Journal of Gastroenterology, 13, 4669-4672.
  20. Hamaguchi, M., Kojima, T., Takeda, N., Nakagawa, T., Taniguchi, H., Fujii, K., Omatsu, T., Nakajima, T., Sarui, H., Shimazaki, M., Kato, T., Okuda, J. and Ida, K. (2005) The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver Disease. Annals of Internal Medicine, 143, 722-728.
  21. Kim, H.M., Kim, D.J., Jung, I.H., Park, C. and Park, J. (2007) Prevalence of the Metabolic Syndrome among Korean Adults Using the New International Diabetes Federation Definition and the New Abdominal Obesity Criteria for the Korean People. Diabetes Research and Clinical Practice,77,99-106. http://dx.doi.org/10.1016/j.diabres.2006.10.009
  22. Seo, H.I., Cho, Y.K., Lee, W.Y., Rhee, E.J., Sung, K.C., Kim, B.S., Son, B.H., Shin, J.H., Joo, K.J., Hong, H.P., Chae, S.W. and Jin, W. (2012) Which Metabolic Syndrome Criteria Best Predict the Presence of Non-Alcoholic Fatty Liver Disease? Diabetes Research and Clinical Practice, 95,19-24. http://dx.doi.org/10.1016/j.diabres.2011.08.013
  23. Kotronen, A. and Yki-Järvinen, H. (2008) Fatty Liver: A Novel Component of the Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, 27-23. http://dx.doi.org/10.1161/ATVBAHA.107.147538
  24. Aguirre, L., Hijona, E., Macarulla, M.T., Gracia, A., Larrechi. I., Bujanda. L., Hijona, L. and Portillo, M.P. (2013) Several Statins Increase Body and Liver Fat Accumulation in a Model of Metabolic Syndrome. Journal of Physiology and Pharmacology, 64, 281-288.
  25. Tsai, C.H., Li, T.C. and Lin, C.C. (2008) Metabolic Syndrome as a Risk Factor for Non-Alcoholic Fatty Liver Disease. Southern Medical Journal,101,900-905.

International Journal of Scientific Research in Science and Technology

Downloads

Published

2023-06-30

Issue

Volume 10, Issue 3, May-June-2023

Section

Research Articles

License

Copyright (c) IJSRST

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

[1]
Kanika, Prashant "Effect of Bergamot Polyphenolic Fraction on level of HDL-C & LDL-C" International Journal of Scientific Research in Science and Technology(IJSRST), Online ISSN : 2395-602X, Print ISSN : 2395-6011,Volume 10, Issue 3, pp.274-281, May-June-2023.